Diagnosis of lung cancer in individuals with solitary pulmonary nodules by plasma microRNA biomarkers by Shen, Jun et al.
RESEARCH ARTICLE Open Access
Diagnosis of lung cancer in individuals with
solitary pulmonary nodules by plasma microRNA
biomarkers
Jun Shen
1, Ziling Liu
2, Nevins W Todd
3, Howard Zhang
3, Jipei Liao
1, Lei Yu
1, Maria A Guarnera
1, Ruiyun Li
4,
Ling Cai
5, Min Zhan
5 and Feng Jiang
1*
Abstract
Background: Making a definitive preoperative diagnosis of solitary pulmonary nodules (SPNs) found by CT has
been a clinical challenge. We previously demonstrated that microRNAs (miRNAs) could be used as biomarkers for
lung cancer diagnosis. Here we investigate whether plasma microRNAs are useful in identifying lung cancer among
individuals with CT-detected SPNs.
Methods: By using quantitative reverse transcriptase PCR analysis, we first determine plasma expressions of five
miRNAs in a training set of 32 patients with malignant SPNs, 33 subjects with benign SPNs, and 29 healthy
smokers to define a panel of miRNAs that has high diagnostic efficiency for lung cancer. We then validate the
miRNA panel in a testing set of 76 patients with malignant SPNs and 80 patients with benign SPNs.
Results: In the training set, miR-21 and miR-210 display higher plasma expression levels, whereas miR-486-5p has
lower expression level in patients with malignant SPNs, as compared to subjects with benign SPNs and healthy
controls (all P ≤ 0.001). A logistic regression model with the best prediction was built on the basis of miR-21, miR-
210, and miR-486-5p. The three miRNAs used in combination produced the area under receiver operating
characteristic curve at 0.86 in distinguishing lung tumors from benign SPNs with 75.00% sensitivity and 84.95%
specificity. Validation of the miRNA panel in the testing set confirms their diagnostic value that yields significant
improvement over any single one.
Conclusions: The plasma miRNAs provide potential circulating biomarkers for noninvasively diagnosing lung
cancer among individuals with SPNs, and could be further evaluated in clinical trials.
Background
Lung cancer is the second most common cancer and the
number one cancer killer in the USA and worldwide [1].
Lung cancer is often diagnosed at an advanced stage. The
5-year survival rate for stage IV lung cancer is only 10%,
whereas approximately 80% for stage IA disease [2,3].
These statistics provide the primary rationale to improve
lung cancer screening and early detection [4]. Chest X-
ray and sputum cytology have been used for lung cancer
screening. However, the sensitivity was low [2,3]. Several
randomized trials in the USA and Europe have been
carried out with the hope that high-resolution CT ima-
ging can detect lung cancer earlier, much as screening
has done for breast and colorectal cancer [5,6]. Recently,
the National Lung Screening Trial sponsored by the
National Cancer Institute determines that CT scan offers
a lung cancer-specific mortality reduction of 20.3% com-
pared with X-ray in people who are at high risk to
develop lung cancer [5-8]. Given the continued efforts to
search for proof that lung cancer early detection can
improve outcomes of the malignancy, this is certainly an
exciting and encouraging finding. However, the wide-
spread use and improved sensitivity of CT dramatically
increase the number of solitary pulmonary nodules
(SPNs) seen in asymptomatic individuals. Yet only a
small fraction of SPNs are lung tumors [9-12]. Therefore,
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sis of SPNs so that lung cancer can be found in the
earliest, most curable stage, while sparing benign growths
from invasive biopsies and treatments [7,10-12].
The Fleischner Society [7,9] proposes a work-up for
managements of SPNs, which includes surgical resection,
transthoracic needle biopsy, and observation with serial
chest radiographs. Each approach has advantages and dis-
advantages [9-12]. Surgery is the diagnostic criterion stan-
dard and definitive treatment for malignant SPNs, but
should be avoided in cases of benign growths. Needle
biopsy can establish a specific benign or malignant diagno-
sis, but is invasive, potentially risky, and sometimes non-
diagnostic [9]. Observation with serial chest radiographs
avoids unnecessary surgery in cases of benign disease but
delays appropriate diagnosis and treatment, when malig-
nancy is really existent [8]. Furthermore, the non-surgical
approaches may lead to unnecessary radiation exposure,
procedures, anxiety, cost, and low accuracy [9,10]. There-
fore, it is clinically important to develop new techniques
for noninvasively diagnosing lung cancer with high accu-
racy. One approach is to identify lung cancer-associated
molecular genetic changes in biological fluids, and hence
develop noninvasive and cost-effective biomarkers. Blood
is an easily accessible and rich body fluid. Furthermore,
blood plasma contains cell-free DNA and RNA that pro-
vide potential circulating biomarkers [13]. A handful of
lung cancer-related molecular genetic abnormalities have
been identified in last decades [13,14]. Yet none has pro-
vided sufficient evidence to be clinically useful for lung
cancer diagnosis [15].
MicroRNAs (miRNAs) play important functions in
diverse biological processes, including development, cell
proliferation, differentiation, and apoptosis [16]. miRNAs
can transcriptionally regulate expressions of more than
30% of human protein coding genes [16,17]. Some miR-
NAs act as oncogenes or tumor suppressors in tumori-
genesis [17]. Therefore, the altered miRNA expressions
can contribute to the development and progression of
tumorigenesis [18]. Furthermore, specific over- or under-
expression of some miRNAs correlate with particular
tumor types, and thus open up a new field for molecular
diagnosis of cancer [19-22]. For instance, measuring
expression levels of a single miRNA, miR-205, in surgi-
cally resected lung tumor tissues can identify squamous
cell carcinoma of the lungs with 96% sensitivity and 90%
specificity [22]. In addition, measuring blood-based
miRNA expressions can be used to predict survival of
lung cancer patients [23-25]. Therefore, plasma miRNAs
could function as circulating biomarkers. We recently
showed that aberrant plasma expressions of miRNAs
could distinguish lung cancer patients from healthy indi-
viduals [26-29].
The objective of the current study was to investigate
whether the plasma miRNAs have the potential to be used
as biomarkers in identification of lung cancer among indi-
viduals with CT-detected SPNs. Our results show that
combined use of three miRNAs might provide circulating
biomarkers for distinguishing lung tumors from benign
SPNs.
Methods
Patients and clinical specimens
Sixty-five patients with SPNs were used as a training set
for discovery of miRNA biomarkers. The patients con-
sisted of 32 individuals who had malignant SPNs and 33
subjects with benign SPNs. Twenty nine healthy smokers
without SPN were also recruited as controls. The demo-
graphic and clinical variables of the cases and controls are
shown in Table 1. Furthermore, an independent group of
156 patients who had SPNs was used as a testing set for
validation of the miRNA biomarker. The testing set con-
sisted of 76 patients with malignant SPNs and 80 patients
with benign SPNs, whose demographic and clinical vari-
ables are shown in Table 2. All patients were selected
based on presence of SPNs on chest CT scan. Final diag-
noses were confirmed with histopathologic examinations
of specimens obtained by CT-guided transthoracic needle
biopsy, transbronchial biopsy, videotape-assisted thoraco-
scopic surgery, or surgical resection. The study was
approved by appropriate institutional review boards. Ten
ml of peripheral blood was drawn from the subjects using
standardized phlebotomy procedures in BD Vacutainer
spray-coated K2EDTA Tubes (BD, Franklin Lakes, NJ).
The blood samples from cancer patients were collected
prior to definitive surgery, administration of anesthesia,
and adjuvant therapy. The specimens were processed
within 2 hours of collection by centrifugation at 1,300 × G
for 10 minutes at 4°C. Plasma was transferred to a fresh
tube and stored at -80°C until use.
RNA isolation
RNA was extracted from plasma by using a mirVana
miRNA Isolation Kit (Ambion, Austin, TX) as described
in our previous study [25-28]. Purity and concentration of
RNA were determined by using a dual beam UV spectro-
photometer (Eppendorf AG, Hamburg, Germany). Integ-
rity of RNA was determined by using a Bioanalyzer 2100
(Agilent Technologies, Santa Clara, CA). RNA samples
with an RNA integrity number > 8 underwent in further
analysis.
Quantitative reverse transcriptase PCR (qRT-PCR)
qRT-PCR was carried out with TaqMan MicroRNA RT
Kit (Applied Biosystems, Foster City, CA) as described
in our published works [26-29]. Expression levels of five
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cycle threshold (Ct) method with the equation 2-ΔΔCt.
The five miRNAs included miRs-21, 126, 210, 375,
and 486-5p. Ct values of the target miRNAs were
normalized in relation to that of miR-16. MiR-16 was
proven as one of commonly used internal control genes
to determine expressions of miRNAs as showed in our
and others’ previous work [29,30].
Table 1 The demographic and clinical variables of a training set of patients with malignant SPNs, patients with
benign SPNs, and healthy smokers
32 Patients with malignant SPNs 33 Patients with benign SPNs 29 Healthy controls
Age, Median (SD) 66.2 (8.3) 64.7 (12.9) 66.5 (7.1)
Sex
Female 12 (37.5%) 13(39.4%) 10 (34.5%)
Male 20 (62.5%) 20 (60.6%) 19 (65.5%)
Race
African American 8 (25.0%) 9 (27.3%) 8 (27.6%)
White 24 (75.0%) 24 (72.7%) 21 (72.4%)
Nodule size, Median (SD) 2.6 (1.8) 1.1 (1.7)
Pack-years, Median (SD) 35.5 (26.8) 30.0 (30.2) 35.0 (22.8)
Stages of NSCLC
stage I 11 (34.4%)
stage II 8 (25.0%)
stage III-IV 13 (40.6%)
Histological types of NSCLC
AC 18 (56.3%)
SCC 14 (43.7%)
Diagnosis of benign SPNs
Inflammatory lesion 27 (81.8%)
Sarcoid 3 (9.1%)
Granuloma 2 (6.1%)
Fibrosis 1 (3.0%)
Abbreviations: SPNs, solitary pulmonary nodules; SD, standard deviation; NSCLC, non-small-cell lung cancer; AC, adenocarcinoma; SCC, squamous cell carcinoma
Table 2 The demographic and clinical variables of a testing set of patients with malignant SPNs and patients with
benign SPNs
76 patients with malignant SPNs 80 patients with benign SPNs
Age, Median (SD) 67.9 (7.6) 65.4 (13.7)
Sex
Female 34 (44.7%) 30 (37.5%)
Male 42 (55.3%) 50 (62.5%)
Nodule size, Median (SD) 2.5 (1.7) 1.0 (1.4)
Pack-years, Median (SD) 35.5 (23.7) 35.0 (26.7)
Stages of NSCLC
stage I 24 (31.6%)
stage II 30 (39.5%)
stage III-IV 22 (28.9%)
Histological types of NSCLC
AC 40 (52.6%)
SCC 36 (47.4%)
Diagnosis of benign SPNs
Inflammatory lesion 60 (75.0%)
Sarcoid 8 (10.0%)
Granuloma 7 (8.8%)
Fibrosis 5 (6.2%)
Abbreviations: SPNs, solitary pulmonary nodules; SD, standard deviation; NSCLC, non-small-cell lung cancer; AC, adenocarcinoma; SCC, squamous cell carcinoma.
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To determine sample size, we used the area under receiver
operating characteristic curve (AUC) analysis and set the
null hypothesis (H0) at 0.5. Accordingly, at least 28 sub-
jects were required in each category of cases and controls
to show a minimum difference of interest between an
AUC of 0.75 versus an AUC of 0.5 with 80% power at the
5% significance level [31,32]. Therefore, the training and
testing sets of cohorts (Tables 1 and 2) enrolled in the pre-
sent study provided an enough statistical power for identi-
fication and verification of the biomarkers. Pearson’s
correlation analysis was applied to assess relationship
between plasma miRNA expressions and demographic
and clinical characteristics of the patients and control indi-
viduals. The receiver-operator characteristic (ROC) curve
and AUC analyses were used to determine sensitivity, spe-
cificity, and corresponding cut-off value of each miRNA
[31,32]. To decide sensitivity and specificity, clinicopatho-
logic results were used as the reference standards. Logistic
regression was used to develop composite panels of bio-
markers to identify a panel that could distinguish malig-
nant from benign SPNs with the highest sensitivity and
specificity. All analyses including correlation coefficient,
Wilcoxon test, logistic regression, ANOVA, and t test
were performed using log transformed data. All P values
shown were two sided, and a P value of < 0.05 was consid-
ered statistically significant. Graphical displays were pre-
pared by using GraphPad Software (GraphPad Software,
Inc, La Jolla, CA) to show the distributions of plasma
expression for each miRNA in each group.
Results
Identification of miRNAs whose aberrant plasma
expressions are associated with malignant SPNs
Based on our previous work using surgical tissues [26-29],
five miRNAs (miRs-21, 126, 210, 375, and 486-5p) were
selected in this present study. Our previous studies
[26-29] showed that miRs-21, 210, and 375 had higher
expression levels, whereas miRs-126 and 486-5p displayed
lower expression levels in lung tumors compared with
normal lung tissues. In the current study, all miRNAs
tested had ≤ 30 Ct values in each plasma sample. The
results indicated that the miRNAs stably existed in plasma
and could be robustly detectable through qRT-PCR assay.
Plasma expression level for each miRNA was further com-
pared between three groups of subjects in the training set.
As shown in Table 3 and Figure 1, both miR-126 and
miR-375 did not show statistical difference between the
three groups (All P > 0.100). miR-21 and miR-210 dis-
played higher plasma expression levels in patients bearing
benign SPNs compared to healthy smokers (All P ≤
0.001). Furthermore, their plasma expression levels were
even higher in patients with malignant SPNs compared to
individuals with benign SPNs (All P < 0.010). In contrast,
plasma miR-486-5p expression was reduced in patients
with benign SPNs compared to healthy smokers (P <
0.0001). Furthermore, plasma mir-486-5p expression level
in patients having malignant SPNs was even lower com-
pared to patients with benign SPNs (P = 0.0048) (Table 3
and Figure 1). Taken together, miR-21 and miR-210 dis-
played significantly higher plasma expression levels in
patients with malignant SPNs compared to both subjects
having benign SPNs and healthy smokers (Figure 1). miR-
486-5p had considerably lower plasma expression level in
patients bearing malignant SPNs compared to both sub-
jects having benign SPNs and healthy smokers (Figure 1).
Therefore, the three miRNAs present potential plasma
biomarkers for identifying malignant SPNs.
ROC analyses were performed to evaluate the capability
of using the three miRNAs (miRs-21, 210, and 486-5p) to
discriminate patients with malignant SPNs from patients
having benign SPNs. The individual miRNAs exhibited
AUC values of 0.5767-0.6913 (Additional file 1, Table S1;
Additional file 2, Figure S1). As a result, they yielded
56.25-71.80% sensitivity and 57.58-72.73% specificity in
distinguishing malignant from benign SPNs. Furthermore,
using Logistic regression analysis, we identified a linear
combination of values for plasma miRs-21, 210, and 486-
5p expression levels. The three miRNAs used in combina-
tion could create a model to distinguish malignant from
benign SPNs (Table 4). When optimum cut-offs were
selected for the three miRNAs at 5.3941, 2.0008, and
5.0215, respectively, their combined use generated 0.8551
AUC, which was significantly higher than that of any sin-
gle gene alone (P < 0.05). Accordingly, the composite
panel of the three miRNAs revealed 75.00% sensitivity and
84.85% specificity in diagnosis of lung cancer from CT-
detected SPNs. The parameters were significantly higher
compared with that of individual miRNAs (all p < 0.05).
Taken together, combined analysis of the three miRNAs
had a reasonable power to identify lung tumors in patients
with SPNs.
Pearson correlation analysis indicated that the estimated
correlations among expression levels of the three miR-
NAs in plasma were low (All P > 0.05) (Additional file 3,
Table S2). The data suggested that expressions of the
miRNAs were complementary to each other, and further
supported that combing the three genes outperformed a
single one used alone. Furthermore, none of the three
miRNAs had statistical differences in term of diagnostic
sensitivity and specificity between different stages of lung
tumors (P > 0.05) (Additional file 4, Table S3). In addi-
tion, there was no association of the changes of the genes
with the age, gender, ethnicity, and histological type of
the participants (All p > 0.05), but their smoking pack-
years (p < 0.05) (Additional file 4, Table S3). Moreover,
plasma expression levels of the miRNAs were related to
size of SPNs (p < 0.05) (Additional file 4, Table S3).
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and controls
To further evaluate the diagnostic performance of the
small miRNA panel, the three miRNAs were assessed in
a testing cohort (Table 2). miR-21 and miR-210 displayed
higher plasma expression levels in patients with malig-
nant SPNs compared to individuals having benign SPNs
(All p < 0.05). In contrast, miR-486-5p had lower expres-
sion level in patients with malignant SPNs compared to
individuals having benign SPNs (P < 0.01). The observa-
tions were in agreement with the findings observed in
the above training test. Furthermore, we used the optimal
thresholds established in the above training set to deter-
mine diagnostic performance of the miRNAs in the test-
ing set. The panel of the three miRNAs produced 76.32%
sensitivity and 85.00% specificity in differentiating malig-
nant from benign SPNs (Table 5). The three miRNAs
had no statistical differences of diagnostic sensitivity and
Table 3 Expression levels of plasma miRNAs in healthy smokers, patients with benign SPNs, and patients with
malignant SPNs
Healthy smokers Patients with benign SPNs Patients with malignant SPNs
MiRNAs Expression levels of each miRNA, Median (SD)
miR-375 1.698 (0.1996) 1.611 (0.3110) 1.735 (0.3027)
miR-126 7.531 (1.050) 6.133 (0.6545) 6.292 (0.6652)
miR-21 0.639 (0.4707) 4.401 (1.2820)
□ 5.47 (1.3450)*
miR-210 1.126 (0.2952) 1.769 (0.4759)
□ 2.252 (0.6174)*
miR-486-5p 8.088 (1.3610) 5.668 (1.641)
□ 4.019 (1.6290)*
SPNs, solitary pulmonary nodules; SD, standard deviation. *, statistical significance between patients with malignant SPNS and patients with benign SPNs. □,
statistical significance between patients with benign SPNs and healthy controls.
Figure 1 Comparison of plasma miRNA expressions in healthy smokers, patients with benign SPNs, and patients with malignant SPNs.
Horizontal lines indicate mean values. *, statistical significance (P < 0.05) between patients with benign SPNs and healthy controls.
□, statistical
significance (P < 0.05) between patients with malignant SPNs and healthy controls. ª, statistical significance (P < 0.05) between patients with
malignant SPNs and patients with benign SPNs.
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(Table 5). Furthermore, the changes of the genes had no
association with the age, gender, and histological type of
the participants (All p > 0.05), except their smoking
pack-years (p < 0.05) (Additional file 5, Table S4). Finally,
plasma expressions of the miRNAs were correlated to
size of SPNs (p < 0.05) (Additional file 5, Table S4). Alto-
gether, the validation data created from the testing set
confirmed that the miRNAs had the potential to be used
as biomarkers for lung tumors among individuals with
CT-detected SPNs.
Discussion
In the present study, we investigate whether plasma miR-
NAs could be useful in distinguishing malignant from
benign SPNs discovered by CT scan. We first determine
plasma expression levels of five miRNAs in a training set
of cases and controls. We find that three miRNAs used
in combination has higher diagnostic efficiency for lung
cancer than does any single one. Furthermore, the valida-
tion of the miRNA panel in a testing set confirms that
the three genes could provide biomarkers for lung cancer
diagnosis in subjects with SPNs.
As an oncomir, up-regulation of miR-21 leads to tumor
development and progression [33-35]. Circulating miR-21
has been described as a biomarker for different tumor
entities [36,37]. For instance, we recently found that miR-
21 was one of plasma miRNAs that could differentiate
early stage lung cancer patients from healthy non-smoking
individuals [29]. miR-486-5p was shown to regulate tumor
progression and OLFM4 anti-apoptotic factor [38].
Furthermore, miR-486-5p was underexpressed in several
types of solid tumors [25,39,40]. We also found that miR-
486-5p displayed lower expression levels in lung tumor tis-
sues compared with the paired normal lung tissues [26,29].
In line with the previous findings in tissue specimens, the
current study shows that plasma miR-486-5p expression
in lung cancer patients is significantly lower compared to
subjects with both benign SPNs and healthy smokers. The
findings in both surgical tissues and plasma specimens
suggest that miR-486-5p down-regulation might play a
role as a tumor suppressor in lung tumorigeneisis. We are
pursuing a study to investigate possible mechanism of
down-regulation of miR-486-5p in the development and
progress of lung cancer. miR-210 regulates the hypoxic
response of tumor cells and tumor growth [41]. Overex-
pression of miR-210 is related to aggressiveness of breast
and oral cancers [42]. Furthermore, up-regulation of miR-
210 can mediate mitochondrial alterations associated with
modulation of HIF-1 activity in late stages of lung cancer
[43]. In addition, elevated miR-210 expressions in serum
could be used as one of biomarkers for diffuse large B-cell
lymphoma and pancreatic cancer [44,45]. We recently
reported that miR-210 might be a plasma biomarker for
diagnosis of early stage non-small-cell lung cancer [29]. In
the present study, we extend our previous findings by
demonstrating that the miRs-21, 210, and 486-5p have the
potential to be used as circulating biomarkers for distin-
guishing malignant from benign SPNs detected by CT.
Major causes of benign SPNs include chronic smoking,
granuloma, and infections, et al [9,12]. These benign dis-
eases could exhibit some molecular changes [4,46-48].
Therefore, it is not surprise to find that individuals with
benign SPNs have higher degrees of aberrant plasma
expressions of miRNAs compared with healthy individuals.
However, lung cancer patients have even higher degrees of
abnormal plasma expressions of the miRNAs compared
with subjects with benign SPNs. Taken together, lung
cancer patients have higher degrees of abnormal plasma
changes for the three miRNAs compared to both indivi-
duals and healthy smokers. Therefore, the miRNA
Table 4 Panels of biomarkers that differentiate malignant from benign SPNs determined by Logistic regression
analysis
Mann-Whitney
ROC model Area Standard error 95% Wald confidence limits
miR-21 and miR-210 0.775 0.0582 0.6606 0.8886
miR-21 and miR-486-5p 0.773 0.0581 0.6588 0.8867
miR-210 and miR-486-5p 0.814 0.0527 0.7111 0.9177
miR-21, miR-210, and miR-486-5p 0.855 0.0456 0.7657 0.9445
ROC, the receiver-operator characteristic curve; AUC, the area under receiver operating characteristic curve.
Table 5 Diagnostic performance of the composite panel
of three miRNAs in a testing cohort of patients with
malignant SPNs and patients with benign SPNs
Sensitivity Specificity
All cases 76.32% 85.00%
Different histological types *
AC 75.00% 85.00%
SCC 77.78% 85.00%
Cases with different stages *
I 75.00% 85.00%
II 80.00% 85.00%
III-IV 72.73% 85.00%
Abbreviations: SPNs, solitary pulmonary nodules; SCC, squamous cell
carcinoma; AC, adenocarcinoma. *P > 0.05.
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subjects bearing benign SPNs and healthy smokers.
Analysis of cancer-associated miRNAs in blood for lung
cancer diagnosis has been investigated by several labora-
tories [29,49-51]. For instance, Boeri et al recently showed
that specific miRNA signatures in plasma could be useful
for lung cancer diagnosis and identifying the onset of
aggressive disease even before spiral-CT detection [50].
The finding from our current research supports the pre-
vious observations. Moreover, the sensitivity and specifi-
city of combined use of the three plasma miRNAs for
identifying malignant SPNs is higher compared with indi-
vidual genes. Given the accuracy, future combined use of
the miRNAs with CT will overcome the weakness of
the imaging analysis that has low sensitivity in the early
detection of lung cancer. Such combination will also
surmount major obstacle of circulating biomarkers, which
cannot localize tumor location. This concept is supported
by our recent study in which, we demonstrated that
combined use of sputum-based genomic probes with CT
increased the diagnostic efficiency for stage I lung cancer
compared with CT used alone [52]. Therefore, the plasma
miRNAs would be an aid to decision making in the man-
agement of lung SPNs. In addition, it has been believed
that malignant lesions of the lungs are more common in
bigger SPNs [9]. Because the identified miRNAs whose
aberrations are malignancy-related changes, it is not sur-
prise to find that there is statistical correlation between
expression levels of the genes with size of SPNs. Moreover,
none of the circulating miRNAs shows correlation to his-
tological subtypes. Interestingly, altered expressions of the
miRNAs are found not only in advanced stage, but also in
early stage lung cancers. The discovery might be an
important characteristic if the miRNAs are to be employed
for the early detection of the malignancy.
Our result appears promising, because compared with
current techniques, the assay is less expensive and a non-
invasive approach, thus offering a potential cost-effective
approach in discriminating malignant from benign SPNs.
However, the miRNAs biomarkers have several limita-
tions. First, the panels of biomarkers were selected from a
limited numbers of miRNA candidates. Other important
miRNAs might not be included. Therefore, the accuracy
of the miRNA-based biomarkers for identifying malignant
SPNs is not high enough to be used in clinical settings. To
overcome the obstacle, we are applying comprehensive
miRNA microarrays to analyze plasma miRNA profile of
patients with malignant SPNs, and comparing to those in
patients with benign SPNs. The globally search for gen-
ome-wide miRNA profiling will identify additional more
informative miRNAs for malignant SPNs. The important
miRNAs can be added to the current ones to improve the
diagnostic efficacy of the plasma miRNA biomarkers.
Second, malignant SPNs are highly heterogeneous: most
of malignant SPNs are primary lung tumors, and some are
metastases from other organs. Whether the three miRNAs
are useful in detection of metastatic cancer in the lungs
remains to be investigated.
Conclusions
We report the identification and evaluation of a small
panel of miRNAs that provides potential biomarkers for
diagnosis of lung cancer in subjects with CT-found
SPNs. Nevertheless, undertaking a multicenter clinical
trial in a large population to prospectively validate our
current findings is certainly needed. After the compre-
hensive and definite validation, future use of the biomar-
kers would complement CT in lung cancer screening for
the early detection of lung cancer.
Additional material
Additional file 1: AUC values and corresponding sensitivity and
specificity of single miRNAs for distinguishing lung cancer from
benign SPNs. AUC, the area under receiver operating characteristic
curve.
Additional file 2: ROC curves analysis of expression levels of plasma
miRNAs. ROC curves analysis of expression levels of plasma miRNAs in
32 patients with malignant SPNs and 33 patients with benign SPNs. The
AUC conveys accuracy miRNA in distinguishing malignant from benign
SPNs in terms of sensitivity and specificity. A-E show ROC curves of five
individual miRNAs, respectively. F shows ROC curve of combined three
miRNAs, miR-21, miR-210, and miR-486-5p, a composite panel.
Additional file 3: Pearson correlation analysis of coefficients
between the three miRNAs. Coefficients between the three miRNAs
were determined by using Pearson Correlation analysis.
Additional file 4: Relationship between plasma miRNA expressions
and clinical characteristics. Relationship between plasma miRNA
expressions and demographic and clinical characteristics of the patients
and control individuals was analysed by Spearman rank correlation.
Additional file 5: Relationship between the three miRNAs and
clinical characteristics. Relationship between the three miRNAs and
demographic and clinical characteristics of the patients with malignant
SPNs and patients with benign SPNs was determined by Spearman rank
correlation.
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